All In Biotech

NDA 021840 · Teva Branded Pharm

Seasonique

Ethinyl Estradiol, Levonorgestrel · Oral

Last checked: Nov 19, 2026Latest source record: Jan 27, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

May 25, 2006

Approved uses

2

Original approval plus efficacy supplements

Registered trials

501

113 Phase 3, 20 recruiting

FAERS reports

200

73 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs , including CAMRESE, are contraindicated in women who are over 35 years of age and smoke. [See Contraindications ( 4 ) and Warnings and Precautions ( 5.1 )]. WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS See full prescribing information for complete boxed warning. CAMRESE is contraindicated in women over 35 years old who smoke. Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use.

What it is approved for

From the label in effect Oct 31, 2024.

CAMRESE ® is indicated for use by females of reproductive potential to prevent pregnancy. CAMRESE is a combination of levonorgestrel, a progestin, and ethinyl estradiol, an estrogen, indicated for use by females of reproductive potential to prevent pregnancy. ( 1 )

Mechanism: COCs prevent pregnancy primarily by suppressing ovulation.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • SEASONIQUE · ETHINYL ESTRADIOL 0.03MG,0.01MG; LEVONORGESTREL 0.15MG,N/A · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Ethinyl Estradiol" as an intervention, any sponsor and status, largest first.

All 501 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue15
  • metrorrhagia14
  • nausea11
  • vaginal haemorrhage11
  • headache10
  • pain9
  • drug ineffective8
  • pruritus8
  • rash8
  • anxiety7
  • product substitution issue7
  • somnolence7

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20111
20123
20134
201423
201520
201642
201725
201814
201919
202013
20215
20228
20239
20245
20257
20262

Recalls

1 FDA enforcement reports for this application.

  • Mar 14, 2013 · Class III · Terminated

    Failed Impurity/Degradation Specifications; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) detected during impurity testing

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Seasonique (L-Norgest/E.Estradiol-E.Estrad)

2024 spending

$4K

Beneficiaries

n/a

11 claims

Per beneficiary

n/a

$4.39 per unit

View as table
YearSpending
2020$100,280
2021$101,398
2022$123,250
2023$100,346
2024$4,398

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,068 on PubMed

Sponsor: Teva

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.